{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T19:27:52Z","timestamp":1786390072033,"version":"build-2736575974"},"reference-count":82,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T00:00:00Z","timestamp":1725926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The recent COVID-19 pandemic has significantly challenged blood transfusion services (BTS) for providing blood products and for keeping blood supplies available. The possibility that a similar pandemic event may occur again has induced researchers and transfusionists to investigate the adoption of new tools to prevent and reduce these risks. Similarly, increased donor travelling and globalization, with consequent donor deferral and donor pool reduction, have contributed to raising awareness on this topic. Although recent studies have validated the use of pathogen reduction technology (PRT) for the control of transfusion-transmitted infections (TTI) this method is not a standard of care despite increasing adoption. We present a critical commentary on the role of PRT for platelets and on associated problems for blood transfusion services (BTS). The balance of the cost effectiveness of adopting PRT is also discussed.<\/jats:p>","DOI":"10.3390\/jcm13185359","type":"journal-article","created":{"date-parts":[[2024,9,10]],"date-time":"2024-09-10T09:10:57Z","timestamp":1725959457000},"page":"5359","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Platelet Pathogen Reduction Technology\u2014Should We Stay or Should We Go\u2026?"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2645-8496","authenticated-orcid":false,"given":"Andrea","family":"Piccin","sequence":"first","affiliation":[{"name":"Northern Ireland Blood Transfusion Service (NIBTS), Belfast BT9 7TS, UK"},{"name":"Department of Internal Medicine V, Medical University of Innsbruck, 6020 Innsbruck, Austria"},{"name":"Department of Industrial Engineering, University of Trento, 38122 Trento, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allameddine","family":"Allameddine","sequence":"additional","affiliation":[{"name":"Northern Ireland Blood Transfusion Service (NIBTS), Belfast BT9 7TS, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Spizzo","sequence":"additional","affiliation":[{"name":"Department of Oncology, Brixen Hospital, 39042 Bolzano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6463-5430","authenticated-orcid":false,"given":"Katrina M.","family":"Lappin","sequence":"additional","affiliation":[{"name":"Patrick G Johnston Centre for Cancer Research, Queen\u2019s University Belfast, Belfast BT7 1NN, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Prati","sequence":"additional","affiliation":[{"name":"Servizio Trasfusionale, Ospedale Ca\u2019 Granda, 20122 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/bjh.15030","article-title":"Haematology patients and the risk of transfusion transmitted infection","volume":"180","author":"Ainley","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1111\/trf.15762","article-title":"Bacterial contamination rate of platelet components by primary culture: A systematic review and meta-analysis","volume":"60","author":"White","year":"2020","journal-title":"Transfusion"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2015-07-655944","article-title":"Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance","volume":"127","author":"Hong","year":"2016","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/vox.12670","article-title":"Failure of bacterial screening to detect Staphylococcus aureus: The English experience of donor follow-up","volume":"113","author":"Brailsford","year":"2018","journal-title":"Vox Sang."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.tmrv.2021.05.001","article-title":"Platelet Component False Positive Detection Rate in Aerobic and Anaerobic Primary Culture: A Systematic Review and Meta-Analysis","volume":"35","author":"Corean","year":"2021","journal-title":"Transfus. Med. Rev."},{"key":"ref_6","first-page":"483","article-title":"Budget impact of implementing platelet pathogen reduction into the Italian blood transfusion system","volume":"16","author":"Cicchetti","year":"2018","journal-title":"Blood Transfus."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/tmi.13863","article-title":"Pathogen inactivation methods to prevent transfusion-transmissible arboviruses: A systematic review and meta-analysis","volume":"28","author":"Larrea","year":"2023","journal-title":"Trop. Med. Int. Health"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1046\/j.1537-2995.1998.38198141508.x","article-title":"Current status of solvent\/detergent-treated frozen plasma","volume":"38","author":"Klein","year":"1998","journal-title":"Transfusion"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rebulla, P., and Prati, D. (2022). Pathogen reduction for platelets-a review of recent implementation strategies. Pathogens, 11.","DOI":"10.3390\/pathogens11020142"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/j.1751-2824.2010.01417.x","article-title":"Pathogen inactivation\/reduction of platelet concentrates: Turning theory into practice","volume":"5","author":"Gathof","year":"2010","journal-title":"ISBT Sci. Ser."},{"key":"ref_11","unstructured":"(2024, August 15). Guide to the Preparation, Use and Quality Assurance of Blood Components. European Committee EDQM. 21th Edition 2023. Available online: https:\/\/freepub.edqm.eu\/publications\/AUTOPUB_48\/detail."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/trf.13149","article-title":"Cost implications of implementation of pathogen-inactivated platelets","volume":"55","author":"McCullough","year":"2015","journal-title":"Transfusion"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1423-0410.2012.01614.x","article-title":"Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: Results of a meta-analysis of randomized controlled trials","volume":"103","author":"Cid","year":"2012","journal-title":"Vox Sang."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08227.x","article-title":"Dutch-Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction","volume":"150","author":"Kerkhoffs","year":"2010","journal-title":"Br. J. Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/trf.14589","article-title":"Amotosalen\/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease","volume":"58","author":"Castro","year":"2018","journal-title":"Transfusion"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.2011.08635.x","article-title":"A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion","volume":"153","author":"Lozano","year":"2011","journal-title":"Br. J. Haematol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s13063-022-06137-8","article-title":"The Mirasol Evaluation of Reduction in Infections Trial (MERIT): Study protocol for a randomized controlled clinical trial","volume":"23","author":"Kasirye","year":"2022","journal-title":"Trials"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/S0140-6736(16)00581-X","article-title":"Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: The African Investigation of the Mirasol System (AIMS) randomised controlled trial","volume":"387","author":"Allain","year":"2016","journal-title":"Lancet"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/trf.17498","article-title":"Transfusion-transmission of hepatitis E virus through red blood cell transfusion but not through platelet concentrates: A case report from Spain","volume":"63","author":"Ojea","year":"2023","journal-title":"Transfusion"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1111\/trf.12686","article-title":"Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system","volume":"54","author":"Owada","year":"2014","journal-title":"Transfusion"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/trf.14797","article-title":"Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: From platelet production to patient care","volume":"58","year":"2018","journal-title":"Transfusion"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/trf.17720","article-title":"Results of clinical effectiveness of conventional versus Mirasol-treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial","volume":"64","author":"Koepsell","year":"2024","journal-title":"Transfusion"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Malvaux, N., Defraigne, F., Bartziali, S., Bellora, C., Mommaerts, K., Betsou, F., and Schuhmacher, A. (2022). In Vitro Comparative Study of Platelets Treated with Two Pathogen-Inactivation Methods to Extend Shelf Life to 7 Days. Pathogens, 11.","DOI":"10.3390\/pathogens11030343"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1111\/trf.14534","article-title":"Ultraviolet light-based pathogen inactivation and alloimmunization after platelet transfusion: Results from a randomized trial","volume":"58","author":"Norris","year":"2018","journal-title":"Transfusion"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1423-0410.2004.00548.x","article-title":"Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: Comparisons with pathogen-reduction technology-treated apheresis platelet products","volume":"87","author":"Li","year":"2004","journal-title":"Vox Sang."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/trf.16747","article-title":"Impact of different pathogen reduction technologies on the biochemistry, function, and clinical effectiveness of platelet concentrates: An updated view during a pandemic","volume":"62","author":"Escolar","year":"2022","journal-title":"Transfusion"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000323845","article-title":"UVC Irradiation for Pathogen Reduction of Platelet Concentrates and Plasma","volume":"38","author":"Seltsam","year":"2011","journal-title":"Transfus. Med. Hemother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/trf.15119","article-title":"Bacterial inactivation of platelet concentrates with the THERAFLEX UV-Platelets pathogen inactivation system","volume":"59","author":"Gravemann","year":"2019","journal-title":"Transfusion"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/vox.12888","article-title":"Inactivation of three emerging viruses\u2014Severe acute respiratory syndrome coronavirus, Crimean\u2013Congo haemorrhagic fever virus and Nipah virus\u2014In platelet concentrates by ultraviolet C light and in plasma by methylene blue plus visible light","volume":"115","author":"Eickmann","year":"2020","journal-title":"Vox Sang."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/vox.12936","article-title":"Hepatitis E virus is effectively inactivated in platelet concentrates by ultraviolet C light","volume":"115","author":"Praditya","year":"2020","journal-title":"Vox Sang."},{"key":"ref_31","first-page":"1086","article-title":"Efficacy of UVC-treated, pathogen-reduced platelets versus untreated platelets: A randomized controlled non-inferiority trial","volume":"106","author":"Brixner","year":"2021","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1537-2995.2012.03854.x","article-title":"Pathogen inactivation of platelets using ultraviolet C light: Effect on in vitro function and recovery and survival of platelets","volume":"53","author":"Bashir","year":"2013","journal-title":"Transfusion"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.21037\/aob-21-44","article-title":"THERAFLEX ultraviolet C (UVC)-based pathogen reduction technology for bacterial inactivation in blood components: Advantages and limitations","volume":"7","author":"Schulze","year":"2002","journal-title":"Ann. Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1111\/trf.16112","article-title":"Extension of platelet shelf life with an improved bacterial testing algorithm","volume":"60","author":"Evans","year":"2020","journal-title":"Transfusion"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/vox.12696","article-title":"Optimized processing for pathogen inactivation of double-dose buffy-coat platelet concentrates: Maintained in vitro quality over 7-day storage","volume":"113","author":"Ohlsson","year":"2018","journal-title":"Vox Sang."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/vox.12860","article-title":"Impact of implementing pathogen reduction technologies for platelets on reducing outdates","volume":"115","author":"Gorria","year":"2020","journal-title":"Vox Sang."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/trf.17285","article-title":"Longitudinal analysis of annual national hemovigilance data to assess pathogen reduced platelet transfusion trends during conversion to routine universal clinical use and 7-day storage","volume":"63","author":"Pitman","year":"2023","journal-title":"Transfusion"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1537-2995.2006.00777.x","article-title":"Functional inactivation of white blood cells by Mirasol treatment","volume":"46","author":"Fast","year":"2006","journal-title":"Transfusion"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1111\/trf.13530","article-title":"The role of hemovigilance and postmarketing studies when introducing innovation into transfusion medicine practice: The amotosalen-ultraviolet A pathogen reduction treatment model","volume":"56","author":"Corash","year":"2016","journal-title":"Transfusion"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1111\/j.1537-2995.2010.02984.x","article-title":"Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation","volume":"51","author":"Fast","year":"2011","journal-title":"Transfusion"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1111\/trf.15269","article-title":"Transfusion of pathogen-reduced platelet components without leukoreduction","volume":"59","author":"Sim","year":"2019","journal-title":"Transfusion"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1365-2141.2012.09197.x","article-title":"Developments in the prevention of transfusion-associated graft-versus-host disease","volume":"158","author":"Fast","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/vox.12103","article-title":"Prevention of transfusion-transmitted cytomegalovirus (CMV) infection: Standards of care","volume":"107","author":"Lieberman","year":"2014","journal-title":"Vox Sang."},{"key":"ref_44","unstructured":"(2024, August 15). INTERCEPT Platelets, Technical Data Sheet. Available online: https:\/\/www.interceptbloodsystem.com\/sites\/default\/files\/resources\/prd-tds_00121_v10.0_reduced_file_size_-_secured.pdf."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/trf.15807","article-title":"Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light","volume":"60","author":"Lanteri","year":"2020","journal-title":"Transfusion"},{"key":"ref_46","unstructured":"(2024, August 25). Available online: https:\/\/www.terumobct.com\/Public\/306690232.pdf."},{"key":"ref_47","unstructured":"(2024, August 25). Available online: https:\/\/aob.amegroups.org\/article\/view\/6833\/html."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1111\/trf.12598","article-title":"The efficacy of the ultraviolet\u2009C pathogen inactivation system in the reduction of Babesia divergens in pooled buffy coat platelets","volume":"54","author":"Castro","year":"2014","journal-title":"Transfusion"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/vox.13648","article-title":"West Nile and Usutu viruses are efficiently inactivated in platelet concentrates by UVC light using the THERAFLEX UV-Platelets system","volume":"119","author":"Gravemann","year":"2024","journal-title":"Vox Sang."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1111\/trf.12460","article-title":"Paired analysis of plasma proteins and coagulant capacity after treatment with three methods of pathogen reduction","volume":"54","author":"Coene","year":"2014","journal-title":"Transfusion"},{"key":"ref_51","unstructured":"Ravanat, C., Dupuis, A., Marpaux, N., Naegelen, C., Mourey, G., Isola, H., Laforet, M., Morel, P., and Gachet, C. Is the thrombin generation test, a useful research tool, suitable to characterize therapeutic plasma? In Proceedings of the ISTH 2017, Berlin, Germany, 8\u201313 July 2017."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/1098-1101(2000)15:3<169::AID-JCA2>3.0.CO;2-R","article-title":"Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent\/detergent-treated plasma: Is its decreased protein S activity clinically related to their development of deep venous thromboses?","volume":"15","author":"Flamholz","year":"2000","journal-title":"J. Clin. Apher."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.0958-7578.2004.00478.x","article-title":"Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura","volume":"14","author":"Yarranton","year":"2004","journal-title":"Transfus. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1159\/000323552","article-title":"The Use of Solvent\/Detergent Treatment in Pathogen Reduction of Plasma","volume":"38","author":"Hellstern","year":"2011","journal-title":"Transfus. Med. Hemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/bjh.18109","article-title":"Autoimmune disease and sickle cell anaemia: \u2018Intersecting pathways and differential diagnosis\u2019","volume":"197","author":"Piccin","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/vox.12368","article-title":"Paired comparison of methylene blue- and amotosalen-treated plasma and cryoprecipitate","volume":"110","author":"Backholer","year":"2016","journal-title":"Vox Sang."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.transci.2015.01.008","article-title":"Quantitative analysis of plasma proteins in whole blood-derived fresh frozen plasma prepared with three pathogen reduction technologies","volume":"52","author":"Larrea","year":"2015","journal-title":"Transfus. Apher. Sci."},{"key":"ref_58","first-page":"CD009072","article-title":"Pathogen-reduced platelets for the prevention of bleeding","volume":"7","author":"Estcourt","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pati, I., Masiello, F., Pupella, S., Cruciani, M., and De Angelis, V. (2022). Efficacy and Safety of Pathogen-Reduced Platelets Compared with Standard Apheresis Platelets: A Systematic Review of RCTs. Pathogens, 11.","DOI":"10.3390\/pathogens11060639"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/trf.14042","article-title":"Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies","volume":"57","author":"Rebulla","year":"2017","journal-title":"Transfusion"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jamaoncol.2017.5123","article-title":"Evaluation of the Efficacy of Platelets Treated with Pathogen Reduction Process (EFFIPAP) Study Group. Comparison of the Hemostatic Efficacy of Pathogen-Reduced Platelets vs Untreated Platelets in Patients with Thrombocytopenia and Malignant Hematologic Diseases: A Randomized Clinical Trial","volume":"4","author":"Garban","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1111\/j.1537-2995.2009.02151.x","article-title":"Universal adoption of pathogen inactivation of platelet components: Impact on platelet and red blood cell component use","volume":"49","author":"Osselaer","year":"2009","journal-title":"Transfusion"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1537-2995.2010.02873.x","article-title":"Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: Impact on patient outcomes and component utilization during a 3-year period","volume":"51","author":"Cazenave","year":"2011","journal-title":"Transfusion"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1111\/trf.15511","article-title":"Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days","volume":"59","author":"Infanti","year":"2019","journal-title":"Transfusion"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/vox.12456","article-title":"Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre","volume":"112","author":"Amato","year":"2017","journal-title":"Vox Sang."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/vox.12489","article-title":"Patient outcomes and amotosalen\/UVA-treated platelet utilization in massively transfused patients","volume":"112","author":"Nussbaumer","year":"2017","journal-title":"Vox Sang."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2003-12-4443","article-title":"Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: The SPRINT Trial","volume":"104","author":"McCullough","year":"2004","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"3150","DOI":"10.1111\/trf.16691","article-title":"Estimating the impact on the inventory of implementing pathogen-reduced platelets in Canada","volume":"61","author":"Blake","year":"2021","journal-title":"Transfusion"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1537-2995.2005.00671.x","article-title":"SPRINT Study Group. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: An analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light","volume":"46","author":"Murphy","year":"2006","journal-title":"Transfusion"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.3324\/haematol.2017.164137","article-title":"Amotosalen\/ultraviolet A pathogen inactivation technology reduces platelet activatability, induces apoptosis and accelerates clearance","volume":"102","author":"Stivala","year":"2017","journal-title":"Haematologica"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/trf.14464","article-title":"Mitochondrial DNA multiplex real-time polymerase chain reaction inhibition assay for quality control of pathogen inactivation by ultraviolet C light in platelet concentrates","volume":"58","author":"Kim","year":"2018","journal-title":"Transfusion"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1080\/09537100500129300","article-title":"Effect of the psoralen-based photochemical pathogen inactivation on mitochondrial DNA in platelets","volume":"16","author":"Bugert","year":"2005","journal-title":"Platelets"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/trf.13360","article-title":"Assessment of nucleic acid modification induced by amotosalen and ultraviolet A light treatment of platelets and plasma using real-time polymerase chain reaction amplification of variable length fragments of mitochondrial DNA","volume":"56","author":"Bakkour","year":"2016","journal-title":"Transfusion"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Diallo, I., Benmoussa, A., Laugier, J., Osman, A., Hitzler, W.E., and Provost, P. (2020). Platelet Pathogen Reduction Technologies Alter the MicroRNA Profile of Platelet-Derived Microparticles. Front. Cardiovasc. Med., 7.","DOI":"10.3389\/fcvm.2020.00031"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"3727","DOI":"10.1111\/trf.15575","article-title":"Pathogen inactivation with amotosalen plus UVA illumination minimally impacts microRNA expression in platelets during storage under standard blood banking conditions","volume":"59","author":"Arnason","year":"2019","journal-title":"Transfusion"},{"key":"ref_76","first-page":"84","article-title":"Cost of pathogen reduction for platelets: Reply to Cicchetti et al. Blood Transfus 2018; 16: 483-9","volume":"17","author":"Farrugia","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Farrugia, A. (2023). The Evolution of the Safety of Plasma Products from Pathogen Transmission\u2014A Continuing Narrative. Pathogens, 12.","DOI":"10.3390\/pathogens12020318"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1016\/S0149-2918(03)80288-6","article-title":"Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States","volume":"25","author":"Bell","year":"2003","journal-title":"Clin. Ther."},{"key":"ref_79","first-page":"5","article-title":"Abstracts of the 31st Regional ISBT Congress, ISBT In Focus, Virtual meeting, 2\u20138 June 2021","volume":"116","author":"Davison","year":"2021","journal-title":"Vox Sang."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/trf.16926","article-title":"Cost-effectiveness of pathogen reduction technology for plasma and platelets in Quebec: A focus on potential emerging pathogens","volume":"62","author":"Delage","year":"2022","journal-title":"Transfusion"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1111\/trf.15926","article-title":"Pathogen reduction of double-dose platelet concentrates from pools of eight buffy coats: Product quality, safety, and economic aspects","volume":"60","author":"Rosskopf","year":"2020","journal-title":"Transfusion"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1111\/trf.17774","article-title":"Analyzing and modeling massive transfusion strategies and the role of fibrinogen-How much is the patient actually receiving?","volume":"64","author":"Keltner","year":"2024","journal-title":"Transfusion"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/18\/5359\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:53:08Z","timestamp":1760111588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/18\/5359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,10]]},"references-count":82,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["jcm13185359"],"URL":"https:\/\/doi.org\/10.3390\/jcm13185359","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,10]]}}}